Back to News
Market Impact: 0.3
Mirum Reports Positive ATEBRIOZ Results In Younger Children With FOP
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Mirum Pharmaceuticals reported positive Cohort 2 results from the Phase 2 PROGRESS study of ATEBRIOZ (zilurgisertib) in children aged 6 to under 12 with fibrodysplasia ossificans progressiva (FOP). The report provides no numerical efficacy or safety results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
MIRM0.65
More News
- From Wall Street to Silicon Valley, Anthropic IPO poised to have massive 'trickle-down effect'
- Anthropic’s IPO filing shows explosive growth, risks and staggering costs
- Microsoft offers buyouts to nearly 30% of workforce in ongoing AI shift
- Elon Musk warns more than 200 AI cloud companies face ‘guppy-level death’ as the AI boom runs into a debt crisis
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Meta, SpaceX, Anthropic stoke the AI funding frenzy. What it means for our stocks